Every article, report, and earnings note where DHR appears.
A seven-stock countdown explores quality across life sciences tools, from challenged platforms to profitable analytical, diagnostic, and research franchises.
Danaher Corporation (DHR) rises after a sharp post-earnings selloff as investors reassess its Q2 beat, softer core-growth guidance, and delayed bioprocessing revenue. The rebound reflects a reset in expectations rather than a new catalyst, with light volume suggesting limited confirmation.
Danaher Corporation (DHR) rises after investors step back in following a sharp post-earnings selloff. The company beat quarterly EPS estimates but trimmed full-year revenue growth guidance, sparking a rebound as traders viewed the weakness as timing-related rather than a broken business.
Danaher is seeing better operating momentum across Life Sciences, Diagnostics, and Biotechnology, but the stock still trades at a premium that limits upside. The report keeps a Buy rating with fair value set at $225.
Danaher Corporation (DHR) falls sharply after earnings as investors focus on weaker-than-expected forward guidance rather than the quarter’s beat on revenue and EPS. The selloff reflects a valuation reset for a premium stock priced for stronger growth.
Cue Health Inc. (NASDAQ: HLTH) is expected to list on 2026-07-21 in a priced deal with a $15 to $17 range. The company is pitching connected diagnostics and at-home testing, but shareholders should watch how much of the story still depends on testing demand and regulatory execution.
A seven-stock healthcare countdown spans telehealth, devices, life-science tools, diagnostics, distribution, and managed care, with HIMS, BDX, TMO, DHR, and ABT in focus.
Danaher Corporation (DHR) fell 5.4% after its latest earnings report, even with an EPS beat and a modest guidance raise. Investors focused on soft revenue, weak core growth, and mixed segment performance, especially in Diagnostics, which outweighed the company’s strong margins and cash flow.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate DHR ReportCancel anytime